U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
When InvestingPro’s Fair Value model identified Myriad Genetics (NASDAQ:MYGN) as significantly undervalued in mid-May 2025, the healthcare diagnostics company was trading at just $3.84 per share. Three months later, that analysis has proved remarkably accurate, with the stock surging 65% to $6.32, demonstrating the power of data-driven valuation analysis. For investors seeking similar opportunities, the Most undervalued list continues to highlight potential value plays across the market.
Myriad Genetics, a molecular diagnostics company specializing in genetic testing services, was showing signs of operational improvement despite its depressed stock price. When InvestingPro’s models flagged the opportunity, the company had generated $831.3 million in trailing revenue, though it was still working through profitability challenges with negative EBITDA of $29.2 million.
The Fair Value analysis proved particularly timely, as the stock had experienced six months of consistent declines, with monthly returns ranging from -15% to -25%. This persistent weakness created a significant disconnect between the company’s market value and its intrinsic worth, with InvestingPro’s models calculating nearly 50% potential upside from the May entry point.
The investment thesis has been validated by several positive developments. Myriad’s recent Q2 2025 earnings report exceeded expectations, with revenue growth accelerating and management raising guidance. The company also secured a $200 million credit facility from OrbiMed, strengthening its financial position. Notably, EBITDA losses have narrowed from -$29.2 million to -$17.8 million, showing operational improvement.
InvestingPro’s Fair Value methodology combines multiple valuation approaches, including discounted cash flow analysis, peer comparisons, and analyst consensus targets, to identify pricing inefficiencies. This comprehensive approach helps investors identify opportunities before the broader market recognizes them, as demonstrated by the Myriad Genetics case.
The success of this analysis highlights the importance of having access to sophisticated valuation tools and timely market insights. InvestingPro provides investors with access to Fair Value analyses across thousands of stocks, along with real-time alerts and detailed financial health scores. For investors seeking to replicate this success, InvestingPro’s comprehensive suite of tools can help identify the next potential market-beating opportunity.